fashion -WSS

fashion

author：comprehensive 2025-09-27 19:29:07 - browse：99159

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： At ASCO, AstraZeneca reports strong data for breast cancer drug

WSS

Letters to First Opinion on caregivers, digital health, and more

I learned firsthand about improving diversity in clinical trials

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

ASCO: AstraZeneca's Tagrisso greatly slowed some lung cancers

Study identifies new proteins linked to dementia risk 25 years later

Winning ticket for $1 billion Powerball jackpot sold in California

hotspot

fashion

knowledge

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Letters to First Opinion on caregivers, digital health, and more

Hepatitis C has a cure — but many Americans still lack access to it

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

Drug repurposing or repositioning? The language matters

Hospitals struggle to profit from CAR

Medicare proposal to cover medical devices draws a mixed reaction

I learned firsthand about improving diversity in clinical trials

Heart attack and stroke risk calculators need revising

Vir antibody drug aimed at influenza A fails in clinical trial

entertainment

Hospitals struggle to profit from CAR

Ionis drug prevents swelling attacks due to hereditary angioedema

NIH documents show early flaws of $1.6 billion long Covid program

The Pandemic Treaty must support building strong health systems

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Divers poised to search for children washed away in Pennsylvania flash flood

Wikipedia

focus

knowledge

explore